BridgeBio Pharma, Inc.
BBIO
Classificação em ações
#1615
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Preço da ação
$68.06
Última sincronização: 2026-10-19
Valor de mercado
$13.31B
Variação (1 dia)
2.52%
Variação (1 ano)
20.97%
País
US
Negociar BridgeBio Pharma, Inc. (BBIO)
Categoria
Healthcare
Lucros da BridgeBio Pharma, Inc. (BBIO)
Lucros em Jun 2026 TTM: $-706.17M
De acordo com os últimos relatórios financeiros da BridgeBio Pharma, Inc., os ganhos atuais da empresa são de $-706.17M. Em 2023, a empresa teve ganhos de $-653.25M, uma diminuição em relação a aos ganhos de 2022, que foram de $-484.65M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da BridgeBio Pharma, Inc. de 2017 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-706.17M | 30.24% |
| 2024 | $-542.19M | -17.00% |
| 2023 | $-653.25M | 34.79% |
| 2022 | $-484.65M | -17.36% |
| 2021 | $-586.45M | 16.02% |
| 2020 | $-505.49M | 75.16% |
| 2019 | $-288.59M | 70.31% |
| 2018 | $-169.45M | 286.59% |
| 2017 | $-43.83M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -846.98% |
US
|
|
| $-3.09B | 337.15% |
US
|
|
| $-4.02B | 468.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -376.23% |
NL
|
